Genetic Analysis of Archived Tumor Specimens for Hereditary Colorectal Cancer Syndromes in the Cajuns of Louisiana, a US Founder Population
Clin Transl Gastroenterol. 2021 Sep 21;12(9):e00392. doi: 10.14309/ctg.0000000000000392.ABSTRACTINTRODUCTION: The Louisiana Acadian region (population 1.2 million), home of the Cajuns, has among the highest US colorectal cancer (CRC) rates. Although Cajuns are a known genetic founder population, studies assessing for hereditary CRC have not been performed.METHODS: A retrospective review of 2 hospital cancer registries was performed to identify young (
Source: Clinical Colorectal Cancer - September 21, 2021 Category: Cancer & Oncology Authors: Jordan J Karlitz Amanda Phillips Kelly S Sorrells Shanti Rao Source Type: research

Cancer statistics for the US Hispanic/Latino population, 2021
CA Cancer J Clin. 2021 Sep 21. doi: 10.3322/caac.21695. Online ahead of print.ABSTRACTThe Hispanic/Latino population is the second largest racial/ethnic group in the continental United States and Hawaii, accounting for 18% (60.6 million) of the total population. An additional 3 million Hispanic Americans live in Puerto Rico. Every 3 years, the American Cancer Society reports on cancer occurrence, risk factors, and screening for Hispanic individuals in the United States using the most recent population-based data. An estimated 176,600 new cancer cases and 46,500 cancer deaths will occur among Hispanic individuals in the con...
Source: Clinical Colorectal Cancer - September 21, 2021 Category: Cancer & Oncology Authors: Kimberly D Miller Ana P Ortiz Paulo S Pinheiro Priti Bandi Adair Minihan Hannah E Fuchs Dinorah Martinez Tyson Guillermo Tortolero-Luna Stacey A Fedewa Ahmedin M Jemal Rebecca L Siegel Source Type: research

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
CONCLUSION: In this phase II randomized trial, adavosertib improved PFS compared with AM and demonstrates potential as a well-tolerated therapy for RAS/TP53-mutant mCRC. Further testing is required in this sizable population of unmet need.PMID:34538072 | DOI:10.1200/JCO.21.01435 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Jenny F Seligmann David J Fisher Louise C Brown Richard A Adams Janet Graham Philip Quirke Susan D Richman Rachel Butler Enric Domingo Andrew Blake Emma Yates Michael Braun Fiona Collinson Rob Jones Ewan Brown Emma de Winton Timothy C Humphrey Mahesh Parm Source Type: research

Reconsideration of recurrence and metastasis in colorectal cancer
World J Clin Cases. 2021 Aug 26;9(24):6964-6968. doi: 10.12998/wjcc.v9.i24.6964.ABSTRACTTo discuss recurrence patterns and their significance in colorectal cancer. Preexisting medical hypotheses and the clinical phenomena of recurrence in colorectal cancer were evaluated and integrated. Colorectal cancer recurrence/metastasis consists of two types: recurrence from the activation of dormant cancer cells and recurrence from postoperative residual cancer cells. These two recurrences have their own unique mechanisms, biological behaviors, responses to therapy, and prognoses. For type 1 recurrences, surgical resection should be...
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Rui Wang Qi Su Zhao-Peng Yan Source Type: research

Cost-effective screening using a two-antibody panel for detecting mismatch repair deficiency in sporadic colorectal cancer
CONCLUSION: Considering the cost of the four-antibody panel IHC compared to that of the two-antibody panel IHC, a two-antibody panel of PMS2/MSH6 might be the best choice in terms of balancing cost-effectiveness and accuracy.PMID:34540955 | PMC:PMC8409214 | DOI:10.12998/wjcc.v9.i24.6999 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Jong Beom Kim Young Il Kim Yong Sik Yoon Jihun Kim Seo Young Park Jong Lyul Lee Chan Wook Kim In Ja Park Seok-Byung Lim Chang Sik Yu Jin Cheon Kim Source Type: research

Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer: A case report and review of literature
CONCLUSION: NGS can identify precise predictors of response to neoadjuvant chemotherapy, leading to improved outcomes for CRC patients.PMID:34540965 | PMC:PMC8409210 | DOI:10.12998/wjcc.v9.i24.7099 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Long Zhao Quan Wang Shi-Dong Zhao Jing Zhou Ke-Wei Jiang Ying-Jiang Ye Shan Wang Zhan-Long Shen Source Type: research

Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives
J Clin Transl Res. 2021 Aug 4;7(4):511-522. eCollection 2021 Aug 26.ABSTRACTBACKGROUND: Colorectal cancer (CRC) is one of the most frequent and deadly malignancies worldwide. This specific pathology is composed of various molecular entities, with distinct immunological phenotypes. In addition to KRAS, NRAS, and BRAF mutation status, other druggable alterations such as those in HER2, MET, NTRK, ALK, and ROS1 have been identified in recent years offering new therapeutic options for some patients with CRC.AIM: This review will focus on the molecular biology, immunological fingerprints, and current clinical evidence for the us...
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Rodrigo Motta Santiago Cabezas-Camarero Cesar Torres-Mattos Alejandro Riquelme Ana Calle Alejandro Figueroa Miguel J Sotelo Source Type: research

RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer
This report presents our findings of two individuals with CRC from a single family carrying a likely-pathogenic inherited germline variant in RNF43. The proband (III:1) and the proband's mother (II:2) were diagnosed with mismatch repair proficient CRCs at the age of 50 years and 65 years, respectively. Both patients had BRAFV600E mutated colon tumours, indicating that the CRCs arose in sessile serrated lesions. The germline variant RNF43:c.375+1G>A was identified in both patients. RNA studies showed that this variant resulted in an aberrantly spliced transcript which was predicted to encode RNF43:p.Ala126Ilefs*50 result...
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Reger R Mikaeel Joanne P Young Yun Li Nicola K Poplawski Eric Smith Mehgan Horsnell Wendy Uylaki Yoko Tomita Amanda R Townsend Jinghua Feng Arne Zibat Silke Kaulfu ß Christian M üller G ökhan Yigit Bernd Wollnik Hamish Scott Lesley Rawlings Henry Denae Source Type: research

Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases
J Clin Oncol. 2021 Sep 20:JCO2101993. doi: 10.1200/JCO.21.01993. Online ahead of print.NO ABSTRACTPMID:34541862 | DOI:10.1200/JCO.21.01993 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Robert W Lentz Wells A Messersmith Source Type: research

Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial
J Clin Oncol. 2021 Sep 20:JCO2101839. doi: 10.1200/JCO.21.01839. Online ahead of print.ABSTRACTPURPOSE: To study the impact of transarterial Yttrium-90 radioembolization (TARE) in combination with second-line systemic chemotherapy for colorectal liver metastases (CLM).METHODS: In this international, multicenter, open-label phase III trial, patients with CLM who progressed on oxaliplatin- or irinotecan-based first-line therapy were randomly assigned 1:1 to receive second-line chemotherapy with or without TARE. The two primary end points were progression-free survival (PFS) and hepatic PFS (hPFS), assessed by blinded indepen...
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Mary F Mulcahy Armeen Mahvash Marc Pracht Amir H Montazeri Steve Bandula Robert C G Martin Ken Herrmann Ewan Brown Darryl Zuckerman Gregory Wilson Tae-You Kim Andrew Weaver Paul Ross William P Harris Janet Graham Jamie Mills Alfonso Yubero Esteban Matthew Source Type: research

Compare the Diagnostic and Prognostic Value of MLR, NLR and PLR in CRC Patients
CONCLUSIONS: The present study shows for the first time that MLR rather than NLR and PLR is the better diagnostic marker for colorectal cancer, and NLR may be a better prognostic marker for CRC patients.PMID:34542964 | DOI:10.7754/Clin.Lab.2021.201130 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Yanli Kang Xianjin Zhu Zhen Lin Menglu Zeng Pengchong Shi Yingping Cao Falin Chen Source Type: research

CDH1 germline mutations in a Chinese cohort with hereditary diffuse gastric cancer
CONCLUSION: These data reveal, for the first time, the type and frequency of CDH1 germline mutations in Chinese HDGC and demonstrate that germline CDH1 mutations are a noteworthy contributor to the high frequency of HDGC in Chinese.PMID:34537906 | DOI:10.1007/s00432-021-03775-4 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 19, 2021 Category: Cancer & Oncology Authors: Zhiwen Pan Zhixuan Fu Cong Luo Yejiang Bao Mingli Wang Wenming Cao Xiaohong Xu Source Type: research

DISCO App: study protocol for a randomized controlled trial to test the effectiveness of a patient intervention to reduce the financial burden of cancer in a diverse patient population
Trials. 2021 Sep 17;22(1):636. doi: 10.1186/s13063-021-05593-y.ABSTRACTBACKGROUND: Financial toxicity, the material and psychological burden of the cost of treatment, affects 30-50% of people with cancer, even those with health insurance. The burden of treatment cost can affect treatment adherence and, ultimately, mortality. Financial toxicity is a health equity issue, disproportionately affecting patients who are racial/ethnic minorities, have lower incomes, and are
Source: Clinical Colorectal Cancer - September 18, 2021 Category: Cancer & Oncology Authors: Lauren M Hamel David W Dougherty Seongho Kim Elisabeth I Heath Lorna Mabunda Eyouab Tadesse RaeAnn Hill Susan Eggly Source Type: research

Association of sarcopenia and expression of interleukin-23 in colorectal cancer survival
Clin Nutr. 2021 Aug 30;40(10):5322-5326. doi: 10.1016/j.clnu.2021.08.016. Online ahead of print.ABSTRACTBACKGROUND & AIMS: The relationship between sarcopenia and interleukin-23 (IL-23) has not been reported. We designed this study to investigate this relationship and the association of sarcopenia and interleukin-23 with poor prognosis of colorectal cancer.METHODS: We used the %FINDCUT SAS macro to determine the cutpoints of the skeletal muscle index (SMI) to define sarcopenia in colorectal cancer patients. Immunohistochemical staining was performed to detect high and low IL-23 expression in cancer samples. Clinicopath...
Source: Clinical Colorectal Cancer - September 18, 2021 Category: Cancer & Oncology Authors: Wan-Hsiang Hu Ching-Di Chang Ting-Ting Liu Hong-Hwa Chen Chang-Chun Hsiao Hong-Yo Kang Jiin-Haur Chuang Source Type: research

Why do participants in the Flemish colorectal cancer screening program not undergo a diagnostic colonoscopy after a positive fecal immunochemical test?
Acta Clin Belg. 2021 Sep 16:1-7. doi: 10.1080/17843286.2021.1980675. Online ahead of print.NO ABSTRACTPMID:34530695 | DOI:10.1080/17843286.2021.1980675 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 17, 2021 Category: Cancer & Oncology Authors: Sarah Hoeck Harlinde De Schutter Guido Van Hal Source Type: research

Mismatch Repair Protein Expressions in Cohort of Colorectal Carcinoma Patients in Lagos
CONCLUSION: The frequency of mismatch repair deficiency in CC among Nigerians is high, and presence of right-sided mucinous colon cancer in patients below 50 years is highly suggestive of dMMR status. Mutation studies of larger patient samples to determine the percentage with germline mutation will further our knowledge, and influence therapeutic options for CC.PMID:34531340 | DOI:10.4103/njcp.njcp_104_21 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 17, 2021 Category: Cancer & Oncology Authors: K B Badmos L A Adebayo A O Osinowo A O Lawal M Y Habeebu O Rotimi F B Abdulkareem Source Type: research

Systematic extended posterior right sectionectomy with simultaneous resection of the dorsal part of segment 1 and middle hepatic vein detachment
Clin Case Rep. 2021 Sep 12;9(9):e04803. doi: 10.1002/ccr3.4803. eCollection 2021 Sep.ABSTRACTParenchymal sparing surgery should be the strategy of choice for patients with bilobar liver metastases and lesions within the central liver sites.PMID:34532049 | PMC:PMC8435224 | DOI:10.1002/ccr3.4803 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 17, 2021 Category: Cancer & Oncology Authors: Anton Anatoliyovych Burlaka Awofaa Gogo-Abite Ariadna V Paliichuk Dmytro E Makhmudov Vitalii V Zvirych Andrii V Lukashenko Source Type: research

Distinguishing pure histopathological growth patterns of colorectal liver metastases on CT using deep learning and radiomics: a pilot study
In this study, we evaluated radiomics for preoperative prediction of HGPs on computed tomography (CT), and its robustness to segmentation and acquisition variations. Patients with pure HGPs [i.e. 100% desmoplastic (dHGP) or 100% replacement (rHGP)] and a CT-scan who were surgically treated at the Erasmus MC between 2003-2015 were included retrospectively. Each lesion was segmented by three clinicians and a convolutional neural network (CNN). A prediction model was created using 564 radiomics features and a combination of machine learning approaches by training on the clinician's and testing on the unseen CNN segmentations....
Source: Clinical Colorectal Cancer - September 17, 2021 Category: Cancer & Oncology Authors: Martijn P A Starmans Florian E Buisman Michel Renckens Fran çois E J A Willemssen Sebastian R van der Voort Bas Groot Koerkamp Dirk J Gr ünhagen Wiro J Niessen Peter B Vermeulen Cornelis Verhoef Jacob J Visser Stefan Klein Source Type: research

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
CONCLUSION: In RAS wild-type metastatic colorectal cancer, maintenance therapy with FU/FA plus Pmab induced a significantly superior PFS compared with FU/FA alone. If active maintenance therapy is aspired following induction therapy with FU/FA and oxaliplatin plus Pmab, FU/FA plus Pmab appears to be the most favorable option.PMID:34533973 | DOI:10.1200/JCO.21.01332 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 17, 2021 Category: Cancer & Oncology Authors: Dominik Paul Modest Meinolf Karthaus Stefan Fruehauf Ullrich Graeven Lothar M üller Alexander Otto K önig Ludwig Fischer von Weikersthal Karel Caca Albrecht Kretzschmar Eray Goekkurt Siegfried Haas Annika Kurreck Arndt Stahler Swantje Held Armin Jarosch Source Type: research

Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy
CONCLUSIONS: CRC metastases treated with SABR had significantly higher rates of LF if they originated from right-sided primary CRC, compared with left-sided. Liver metastases had the highest rates of LF compared with other metastatic sites. Thus, CRC liver metastases and metastases from right-sided CRC may benefit from more aggressive radiotherapy.PMID:34534143 | DOI:10.1097/COC.0000000000000864 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 17, 2021 Category: Cancer & Oncology Authors: Kathryn R K Benson Navjot Sandhu Carrie Zhang Ryan Ko Diego A S Toesca Phoebe E Lee Rie Von Eyben Maximilian Diehn Michael Gensheimer Peter G Maxim Karl Bush Billy W Loo Scott G Soltys Erqi L Pollom Daniel T Chang Source Type: research

DEEP LEARNING COMPUTER-AIDED POLYP DETECTION REDUCES ADENOMA MISS RATE: A U.S. MULTI-CENTER RANDOMIZED TANDEM COLONOSCOPY STUDY (CADeT-CS Trial)
CONCLUSION: In this U.S. multicenter tandem colonoscopy RCT, we demonstrate a decrease in adenoma miss rate and SSL miss rate and an increase in first-pass APC with the use of a CADe-system when compared to HDWL colonoscopy.PMID:34530161 | DOI:10.1016/j.cgh.2021.09.009 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 16, 2021 Category: Cancer & Oncology Authors: Jeremy R Glissen Brown Nabil M Mansour Pu Wang Maria Aguilera Chuchuca Scott B Minchenberg Madhuri Chandnani Lin Liu Seth A Gross Neil Sengupta Tyler M Berzin Source Type: research

Plasma circular RNA hsa_circ_0001821 acts as a novel diagnostic biomarker for malignant tumors
CONCLUSION: Plasma hsa_circ_0001821 possibly is a novel biological marker for malignant tumors.PMID:34523755 | DOI:10.1002/jcla.24009 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Yulan Song Peng Cao Jipeng Li Source Type: research

Plasma circular RNA hsa_circ_0001821 acts as a novel diagnostic biomarker for malignant tumors
CONCLUSION: Plasma hsa_circ_0001821 possibly is a novel biological marker for malignant tumors.PMID:34523755 | DOI:10.1002/jcla.24009 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Yulan Song Peng Cao Jipeng Li Source Type: research

Plasma circular RNA hsa_circ_0001821 acts as a novel diagnostic biomarker for malignant tumors
CONCLUSION: Plasma hsa_circ_0001821 possibly is a novel biological marker for malignant tumors.PMID:34523755 | DOI:10.1002/jcla.24009 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Yulan Song Peng Cao Jipeng Li Source Type: research

Plasma circular RNA hsa_circ_0001821 acts as a novel diagnostic biomarker for malignant tumors
CONCLUSION: Plasma hsa_circ_0001821 possibly is a novel biological marker for malignant tumors.PMID:34523755 | DOI:10.1002/jcla.24009 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Yulan Song Peng Cao Jipeng Li Source Type: research

Plasma circular RNA hsa_circ_0001821 acts as a novel diagnostic biomarker for malignant tumors
CONCLUSION: Plasma hsa_circ_0001821 possibly is a novel biological marker for malignant tumors.PMID:34523755 | DOI:10.1002/jcla.24009 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Yulan Song Peng Cao Jipeng Li Source Type: research

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
CONCLUSIONS: This study highlights the synergistic immunomodulatory effects of REG and aPD1 combination therapy in mediating a sustained inhibition of colon cancer regrowth, strongly warranting clinical evaluation in CRC, including MSS tumors.PMID:34517894 | DOI:10.1186/s13046-021-02043-0 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Dennis Doleschel Sabine Hoff Susanne Koletnik Anne Rix Dieter Zopf Fabian Kiessling Wiltrud Lederle Source Type: research

Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers
CONCLUSIONS: The findings supported multiclonal CRCs resulting from parallel evolution during the progression from adenoma to adenocarcinoma within the mitogen-activated protein kinase pathway, as previously demonstrated, or the mammalian target of rapamycin pathway. Further studies are warranted to elucidate clinical significance and potential targeted therapy for CRC patients with double PIK3CA alterations and impacts on clinical decision-making in patients with multiclonal CRCs harboring divergent PIK3CA mutational status.PMID:34519764 | DOI:10.1093/ajcp/aqab119 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Ming-Tseh Lin Gang Zheng Erika Rodriguez Li-Hui Tseng Vamsi Parini Rena Xian Ying Zou Christopher D Gocke James R Eshleman Source Type: research

Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial
CONCLUSION: DFS did not correlate with OS for liver-only metastatic CRC. Adjuvant chemotherapy with mFOLFOX6 improves DFS among patients treated with hepatectomy for CRC liver metastasis. It remains unclear whether chemotherapy improves OS.PMID:34520230 | DOI:10.1200/JCO.21.01032 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Yukihide Kanemitsu Yasuhiro Shimizu Junki Mizusawa Yoshitaka Inaba Tetsuya Hamaguchi Dai Shida Masayuki Ohue Koji Komori Akio Shiomi Manabu Shiozawa Jun Watanabe Takeshi Suto Yusuke Kinugasa Yasumasa Takii Hiroyuki Bando Takaya Kobatake Masafumi Inomata Y Source Type: research

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
CONCLUSIONS: This study highlights the synergistic immunomodulatory effects of REG and aPD1 combination therapy in mediating a sustained inhibition of colon cancer regrowth, strongly warranting clinical evaluation in CRC, including MSS tumors.PMID:34517894 | DOI:10.1186/s13046-021-02043-0 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Dennis Doleschel Sabine Hoff Susanne Koletnik Anne Rix Dieter Zopf Fabian Kiessling Wiltrud Lederle Source Type: research

Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis
Clin Exp Gastroenterol. 2021 Aug 29;14:343-351. doi: 10.2147/CEG.S237653. eCollection 2021.ABSTRACTUlcerative colitis (UC) is a chronic inflammatory disorder that requires sustained treatment for optimal outcomes. The 5-aminosalicylate (5-ASA) class of medications are first-line for the treatment of mild-to-moderate UC but suffer from suboptimal adherence rates in real-world settings. This review summarizes the literature on adherence and patient preference to 5-ASA in patients with UC. We begin by highlighting key studies that measure real-world adherence rates, as well as some of the pitfalls associated with certain tech...
Source: Clinical Colorectal Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Kartikeya Tripathi Jeffrey Dong Brooke F Mishkin Joseph D Feuerstein Source Type: research

Options for Low Rectal Cancer: Robotic Total Mesorectal Excision
Clin Colon Rectal Surg. 2021 Sep;34(5):311-316. doi: 10.1055/s-0041-1726449. Epub 2021 Sep 8.ABSTRACTLow rectal cancers (LRCs) may offer a difficult technical challenge even to experienced colorectal surgeons. Although laparoscopic surgery offers a superior exposure of the pelvis when compared with open approach, its role in rectal cancer surgery has been controversial. Robotic platforms are well suited for difficult pelvic surgery due to its three-dimensional visualization, degree of articulation of instruments, precise movements, and better ergonomics. The robot may be suitable especially in the anatomically narrow pelvi...
Source: Clinical Colorectal Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Felipe F Quezada-Diaz J Joshua Smith Source Type: research

Robotic Transanal Surgery for Rectal Cancer
Clin Colon Rectal Surg. 2021 Sep;34(5):317-324. doi: 10.1055/s-0041-1729864. Epub 2021 Sep 9.ABSTRACTRobotic transanal surgery is the culmination of major developments in rectal cancer management and minimally invasive surgery. It is the result of continuous efforts to tackle the challenges inherent to rectal cancer surgery. This latest technology holds great promise and excitement for the care of the rectal cancer patient. In this article, we will describe the evolution of transanal rectal cancer surgery and describe how the convergence of transanal transabdominal, transanal endoscopic microsurgery, transanal minimally in...
Source: Clinical Colorectal Cancer - September 13, 2021 Category: Cancer & Oncology Authors: John H Marks Rafael E Perez Jean F Salem Source Type: research

Liver transplantation in malignant disease
World J Clin Oncol. 2021 Aug 24;12(8):623-645. doi: 10.5306/wjco.v12.i8.623.ABSTRACTLiver transplantation for malignant disease has gained increasing attention as part of transplant oncology. Following the implementation of the Milan criteria, hepatocellular carcinoma (HCC) was the first generally accepted indication for transplantation in patients with cancer. Subsequently, more liberal criteria for HCC have been developed, and research on this topic is still ongoing. The evident success of liver transplantation for HCC has led to the attempt to extend its indication to other malignancies. Regarding perihilar cholangiocar...
Source: Clinical Colorectal Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Sven Arke Lang Jan Bednarsch Zoltan Czigany Katharina Joechle Andreas Kroh Iakovos Amygdalos Pavel Strnad Tony Bruns Daniel Heise Florian Ulmer Ulf Peter Neumann Source Type: research

Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer
CONCLUSION: Women were prone to early DLTs during adjuvant CAPOX in the current study. Doctors should be aware of the sex difference in the incidence of early DLTs, and adjust the CAPOX dosage and provide supportive care for female CRC patients.PMID:34516723 | DOI:10.1111/ijcp.14863 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Hiroaki Nozawa Kazushige Kawai Kazuhito Sasaki Koji Murono Shigenobu Emoto Yuichiro Yokoyama Shinya Abe Junko Kishikawa Yuzo Nagai Hirofumi Sonoda Hiroyuki Anzai Tsuyoshi Ozawa Soichiro Ishihara Source Type: research

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial
J Clin Oncol. 2021 Sep 13:JCO2101436. doi: 10.1200/JCO.21.01436. Online ahead of print.ABSTRACTPURPOSE: Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (OS). FOCUS4-N was set up to explore the impact of oral maintenance therapy in patients who are responding to first-line therapy.METHODS: FOCUS4 was a molecularly stratified trial program that registered patients with newly diagnosed mCRC. The FOCUS4-N trial was offered to patients in ...
Source: Clinical Colorectal Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Richard A Adams David J Fisher Janet Graham Jenny F Seligmann Matthew Seymour Richard Kaplan Emma Yates Mahesh Parmar Susan D Richman Philip Quirke Rachel Butler Ewan Brown Fiona Collinson Stephen Falk Harpreet Wasan Kai-Keen Shiu Gary Middleton Leslie Sa Source Type: research

Treatment Holidays for Patients With Metastatic Colorectal Cancer
J Clin Oncol. 2021 Sep 13:JCO2101999. doi: 10.1200/JCO.21.01999. Online ahead of print.NO ABSTRACTPMID:34516761 | DOI:10.1200/JCO.21.01999 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Pashtoon Murtaza Kasi Source Type: research

Abdominal adipose tissue radiodensity is associated with survival after colorectal cancer
CONCLUSIONS: In patients with nonmetastatic CRC, adipose tissue radiodensity is a novel risk factor for total mortality that is independent of BMI and changes in body weight.PMID:34510172 | DOI:10.1093/ajcn/nqab285 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 12, 2021 Category: Cancer & Oncology Authors: Elizabeth M Cespedes Feliciano Renate M Winkels Jeffrey A Meyerhardt Carla M Prado Lydia A Afman Bette J Caan Source Type: research

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
CONCLUSION: Herein, we reported the status of HRD using a cancer-panel for various solid tumor patients in routine clinical practice and demonstrated that HRD as a single biomarker was not sufficient to predict efficacy of ICIs in solid tumor patients.PMID:34510272 | DOI:10.1007/s00432-021-03781-6 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 12, 2021 Category: Cancer & Oncology Authors: Hana Kim Soomin Ahn Hongsik Kim Jung Yong Hong Jeeyun Lee Se Hoon Park Joon Oh Park Young Suk Park Ho Yeong Lim Won Ki Kang Kyoung-Mee Kim Seung Tae Kim Source Type: research

Abdominal adipose tissue radiodensity is associated with survival after colorectal cancer
CONCLUSIONS: In patients with nonmetastatic CRC, adipose tissue radiodensity is a novel risk factor for total mortality that is independent of BMI and changes in body weight.PMID:34510172 | DOI:10.1093/ajcn/nqab285 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 12, 2021 Category: Cancer & Oncology Authors: Elizabeth M Cespedes Feliciano Renate M Winkels Jeffrey A Meyerhardt Carla M Prado Lydia A Afman Bette J Caan Source Type: research

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
CONCLUSION: Herein, we reported the status of HRD using a cancer-panel for various solid tumor patients in routine clinical practice and demonstrated that HRD as a single biomarker was not sufficient to predict efficacy of ICIs in solid tumor patients.PMID:34510272 | DOI:10.1007/s00432-021-03781-6 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 12, 2021 Category: Cancer & Oncology Authors: Hana Kim Soomin Ahn Hongsik Kim Jung Yong Hong Jeeyun Lee Se Hoon Park Joon Oh Park Young Suk Park Ho Yeong Lim Won Ki Kang Kyoung-Mee Kim Seung Tae Kim Source Type: research

New Indications for Liver Transplantation
J Clin Med. 2021 Aug 28;10(17):3867. doi: 10.3390/jcm10173867.ABSTRACTLiver transplantation (LT) is an important therapeutic option for the treatment of several liver diseases. Modern LT is characterized by remarkable improvements in post-transplant patient survival, graft survival, and quality of life. Thanks to these great improvements, indications for LT are expanding. Nowadays, clinical conditions historically considered exclusion criteria for LT, have been considered new indications for LT, showing survival advantages for patients. In this review, we provide an updated overview of the principal newer indications for L...
Source: Clinical Colorectal Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Alberto Zanetto Sarah Shalaby Martina Gambato Giacomo Germani Marco Senzolo Debora Bizzaro Francesco Paolo Russo Patrizia Burra Source Type: research

Augmented Reality: Moving Robotics Forward
Clin Colon Rectal Surg. 2021 Sep;34(5):345-352. doi: 10.1055/s-0041-1726353. Epub 2021 Sep 3.ABSTRACTCompared with other fields, adoption of robotics in colorectal surgery remains relatively slow. One of the reasons for this is that the expected benefits of robotics, such as greater accuracy, speed, and better patient outcomes, are not born out in evidence comparing use of robotics for colorectal procedures to conventional laparoscopy. But evidence also suggests that outcomes with colorectal robotic procedures depend on the experience of the surgeon, suggesting that a steep learning curve is acting as a barrier to the bene...
Source: Clinical Colorectal Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Nadine Hachach-Haram Danilo Miskovic Source Type: research

Strongly Divergent Impact of Adherence Patterns on Efficacy of Colorectal Cancer Screening: The Need to Refine Adherence Statistics
DISCUSSION: Over a lifelong time frame, large numbers of irregular screening attendees go along with much larger preventive effects than small numbers of perfectly adhering individuals. In clinical practice, efforts to reach as many people as possible at least sporadically should be prioritized over efforts to maximize adherence to repeat screening offers.PMID:34506306 | DOI:10.14309/ctg.0000000000000399 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Thomas Heisser Rafael Cardoso Feng Guo Tobias Moellers Michael Hoffmeister Hermann Brenner Source Type: research

New Indications for Liver Transplantation
J Clin Med. 2021 Aug 28;10(17):3867. doi: 10.3390/jcm10173867.ABSTRACTLiver transplantation (LT) is an important therapeutic option for the treatment of several liver diseases. Modern LT is characterized by remarkable improvements in post-transplant patient survival, graft survival, and quality of life. Thanks to these great improvements, indications for LT are expanding. Nowadays, clinical conditions historically considered exclusion criteria for LT, have been considered new indications for LT, showing survival advantages for patients. In this review, we provide an updated overview of the principal newer indications for L...
Source: Clinical Colorectal Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Alberto Zanetto Sarah Shalaby Martina Gambato Giacomo Germani Marco Senzolo Debora Bizzaro Francesco Paolo Russo Patrizia Burra Source Type: research

Augmented Reality: Moving Robotics Forward
Clin Colon Rectal Surg. 2021 Sep;34(5):345-352. doi: 10.1055/s-0041-1726353. Epub 2021 Sep 3.ABSTRACTCompared with other fields, adoption of robotics in colorectal surgery remains relatively slow. One of the reasons for this is that the expected benefits of robotics, such as greater accuracy, speed, and better patient outcomes, are not born out in evidence comparing use of robotics for colorectal procedures to conventional laparoscopy. But evidence also suggests that outcomes with colorectal robotic procedures depend on the experience of the surgeon, suggesting that a steep learning curve is acting as a barrier to the bene...
Source: Clinical Colorectal Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Nadine Hachach-Haram Danilo Miskovic Source Type: research

Strongly Divergent Impact of Adherence Patterns on Efficacy of Colorectal Cancer Screening: The Need to Refine Adherence Statistics
DISCUSSION: Over a lifelong time frame, large numbers of irregular screening attendees go along with much larger preventive effects than small numbers of perfectly adhering individuals. In clinical practice, efforts to reach as many people as possible at least sporadically should be prioritized over efforts to maximize adherence to repeat screening offers.PMID:34506306 | DOI:10.14309/ctg.0000000000000399 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Thomas Heisser Rafael Cardoso Feng Guo Tobias Moellers Michael Hoffmeister Hermann Brenner Source Type: research

New Indications for Liver Transplantation
J Clin Med. 2021 Aug 28;10(17):3867. doi: 10.3390/jcm10173867.ABSTRACTLiver transplantation (LT) is an important therapeutic option for the treatment of several liver diseases. Modern LT is characterized by remarkable improvements in post-transplant patient survival, graft survival, and quality of life. Thanks to these great improvements, indications for LT are expanding. Nowadays, clinical conditions historically considered exclusion criteria for LT, have been considered new indications for LT, showing survival advantages for patients. In this review, we provide an updated overview of the principal newer indications for L...
Source: Clinical Colorectal Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Alberto Zanetto Sarah Shalaby Martina Gambato Giacomo Germani Marco Senzolo Debora Bizzaro Francesco Paolo Russo Patrizia Burra Source Type: research

Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy
J Cancer Res Clin Oncol. 2021 Sep 9. doi: 10.1007/s00432-021-03792-3. Online ahead of print.ABSTRACTCancer immunotherapy is a major breakthrough in tumor therapy and has been used in monotherapy or combination therapy. However, it has been associated with poor immune tolerance in some patients or immune-related adverse events. Therefore, ideal and reliable tumor elimination strategies are urgently needed to overcome these shortcomings. Phosphatidylserine (PS) is a negatively charged phospholipid, usually present in the inner lobules of eukaryotic cell membranes. Under certain physiological or pathological conditions, PS ma...
Source: Clinical Colorectal Cancer - September 9, 2021 Category: Cancer & Oncology Authors: Jie Zhang Zhujiang Dai Cheng Yan Daorong Wang Dong Tang Source Type: research

Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor
CONCLUSIONS: Our results show the ability of CRC cells to respond to NMU via activation of the NMUR2 receptor, which ultimately leads to a shift in the CRC phenotype towards a more invasive phenotype.PMID:34493299 | PMC:PMC8422652 | DOI:10.1186/s13046-021-02073-8 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Patrycja Przygodzka Ewelina Sochacka Kamila Soboska Marcin Pacholczyk Izabela Papiewska-Paj ąk Tomasz Przygodzki Przemys ław Płociński Steven Ballet An De Prins Joanna Boncela Source Type: research